Based on the aggregated intelligence of 165,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical products giant Johnson & Johnson (NYSE: JNJ) has earned an enviable five-star ranking.

With that in mind, let's take a closer look at Johnson & Johnson's business and see what CAPS investors are saying about the stock right now.

Johnson & Johnson facts

Headquarters (Founded)

New Brunswick, NJ (1886)

Market Cap

$161.7 billion



Trailing-12-Month Revenue

$62.5 billion


CEO William Weldon

CFO Dominic Caruso

Return on Equity (Average, Past 3 Years)


Compound Annual Revenue Growth (Over Past 3 Years)



$18.0 billion / $12.6 billion


Abbott Labs (NYSE: ABT)

Pfizer (NYSE: PFE)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 96.5% of the 12,955 members who have rated Johnson & Johnson believe the stock will outperform the S&P 500 going forward. These bulls include All-Star thievaryx, ranked in the top 10% of our community, and lelandwalker.

Just today, thievaryx argued that Johnson & Johnson's recent recall of some children's medicines would be a short-term blip: "World class company that has been beaten up from the mismanagement of the phantom recall. [J&J] will makes this right and be stronger for it. In the meantime, smile and collect a 3.7% yield that grows almost 10% per annum."

In a pitch from last month, lelandwalker points out why Johnson & Johnson is a compelling long-term buy:

Solid, well managed business. Relatively low priced, pays fair dividends. Although historically price has been more volatile than the indices, over the long haul it has out performed. The company has good numbers (profit margin, revenue, income), stable product line, and some groundbreaking efforts in Alzheimer's treatment Therefore, I expect it to continue to outperform in the long run.

What do you think about Johnson & Johnson, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them.

CAPS is 100% free, so get started!

Jim Royal, PhD. owns no position in any of the companies mentioned. Pfizer is a Motley Fool Inside Value recommendation. Johnson & Johnson is an Income Investor selection and Motley Fool Options has recommended buying calls on its shares. The Fool's disclosure policy always gets a perfect score.